Progress and Future Prospects of Modified Nucleosides as Biological Markers of Cancer

Journal of Chromatography Library

Volumn 45, Issue PC, 1990, Pages C15-C40

  Zumwalt, Robert W ^a   Waalkes, T Phillip ^b   Kuo, Kenneth C ^c   Gehrke, Charles W ^d  

^a UNIVERSITY OF MISSOURI   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Analyt Bio Chem Laboratories Inc   (United States)

^d Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012724411     PISSN: 03014770     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0301-4770(08)61539-0     Document Type: Article

References (44)

1. Borek, E., The morass of tumor markers. Bull. Mol. Biol. Med. 10 (1985), 103–117.
2. Yu, T.F., Weissman, B., Sharney, L., Kupfer, S., Gutman, A.B., On the biosynthesis of uric acid from glycine-N15 in primary and secondary polycythemia. Am. J. Med., 21, 1956, 901.
3. Weissman, B., Bromberg, P.A., Gutman, A.B., The urine bases of human urine. II. Semiquantitative estimation and isotope incorporation. J. Biol. Chem., 224, 1957, 423.
4. Mandel, L.R., Borek, E., The biosynthesis of methylated bases in ribonucleic acid. Biochemistry, 2, 1963, 555.
5. Trewyn, R.W., Grever, M.R., Urinary nucleosides in leukemia: laboratory and clinical applications. CRC Critical Reviews in Clinical Laboratory Sciences 24 (1986), 71–93.
6. Prodi, G., What does “marker” mean. Cimino, F., Birkmayer, G., Klavins, J., Pimentel, E., Salvatore, F., (eds.) Human Tumor Markers, 1987, Walter de Gruyter, Berlin, New York, 3–11.
7. Birkmayer, J.G.D., Paletta, B., New strategies for follow-up of breast cancer patients using CEA. Cimino, F., Birkmayer, G., Klavins, J., Pimentel, E., Salvatore, F., (eds.) Human Tumor Markers, 1987, Walter de Gruyter, Berlin, 621–630 TPA, CA 15–3 and CA 50, in.
8. Tormey, D.C., Waalkes, T.P., Ahman, D.L., Gehrke, C.W., Zumwalt, R.W., Snyder, J., Hansen, H., Biologic markers in breast carcinoma I. Incidences of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides. Cancer 35 (1975), 721–727.
9. Waalkes, T.P., Gehrke, C.W., Blyer, W.A., Zumwalt, R.W., Olwney, C.L.M., Kuo, K.C., Lakings, D.B., Jacobs, S., Potential biological markers in Burkitt's lymphoma. Cancer Chemotherapy Reports 59 (1975), 721–727.
10. Waalkes, T.P., Gehrke, C.W., Zumwalt, R.W., Chang, S.Y., Lakings, D.B., Tormey, D.C., Ahman, D.L., Moertel, C.G., The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer. Cancer 36 (1975), 390–397.
11. R.D. Suits, C.W. Gehrke, Reversed-phase chromatographic separation of nucleic acid bases from DNA and RNA hydrolysates, 18th West Central States Biochemistry Conference, 1975.
12. Gehrke, C.W., Kuo, K.C., Davis, G.E., Suits, R.D., Waalkes, T.P., Borek, E., Quantitative high-performance liquid chromatography of nucleosides in biological materials. J. Chromatogr. 150 (1978), 455–476.
13. Hartwick, R.A., Brown, P.B., Reversed-phase HPLC of nucleosides and bases. J. Chromatogr. 126 (1976), 679–685.
14. Gehrke, C.W., Kuo, K.C., Zumwalt, R.W., Chromatography of nucleosides. J. Chromatogr. 188 (1980), 129–147.
15. Salvatore, F., Savoia, M., Russo, T., Sachetti, L., Cimino, F., Pseudouridine in biological fluids of tumor-bearing patients. Cimino, F., Birkmayer, G., Klavins, J.V., Pimentel, E., Salvatore, F., (eds.) Human Tumor Markers, 1987, Walter de Gruyter, Berlin, New York, 451–462.
16. Heldman, D.A., Grever, M.R., Speicher, C.E., Trewyn, R.W., Urinary excretion of modified nucleosides in chronic myelogenous leukemia. J. Lab. Clin. Med. 101 (1983), 783–792.
17. Rasmuson, T., Bjork, G., Damber, L., Holm, S., Jacobsson, L., Jeppsson, A., Stigbrand, T., Westman, G., Tumor markers in bronchogenic carcinoma, Acta Radiolog. Oncology 22 (1983), 209–214.
18. Oerlemans Lange, F., Major and modified nucleosides as markers in ovarian cancer: a pilot study. Gynecol. Obstet. Invest. 22 (1986), 212–217.
19. Nielsen, H.R., Killman, S., Urinary excretion of β-aminoiso-butyrate and pseudouridine in acute and chronic myeloid leukemia. JNCI 71 (1983), 887–891.
20. Rasmuson, T., Björk, G., Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas. Cancer Detect, and Prevent. 6 (1983), 293–296.
21. Rasmuson, T., Bjork, G.R., Pseudouridine: A prognostic marker in non-Hodgkin's lymphomas, Cancer Detect. Prevent. 8 (1985), 287–290.
22. Mackenzie, J.W., Lewis, R.F., Sisler, G.E., Lin, W., Rogers, J., Clark, I., Urinary catabolites of ribonucleic acid as cancer markers: a preliminary report of their use in patients with lung cancer. Annals of Thoracic Surg. 38 (1984), 133–139.
23. Esposito, F., Russo, T., Ammendola, R., Duilio, A., Salvatore, F., Cimino, F., Pseudouridine excretion and transfer RNA primers for reverse transcriptase in tumors of retroviral origin. Cancer Res. 45 (1985), 6260–6263.
24. T. Heyman, P. Pochart, C.W. Gehrke, K.C. Kuo, : Cell transformation by rous sarcoma virus strongly increases tRNA modification, presented at the international conference on tRNA, Vancouver, British Columbia, July, 1989.
25. Rasmuson, T., Bjork, G.R., Excretion of pseudouridine in urine as a tumor marker in malignant diseases. Bull. Mol. Biol. Med. 10 (1985), 143–154.
26. Heldman, D.A., Grever, M.R., Trewyn, R.W., Differential excretion of modified nucleosides in adult acute leukemia. Blood 61 (1983), 291–296.
27. Heldman, D.A., Grever, M.R., Miser, J.S., Trewyn, R.W., Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia. JNCI 71 (1983), 269–273.
28. Tamuro, S., Amuro, Y., Nakano, T., Fuji, J., Yamamoto, T., Hada, T., Higashino, K., Urinary excretion of pseudouridine in patients with hepatocellular carcinoma. Cancer 57 (1986), 1571–1575.
29. Tamura, S., Fujii, J., Nakano, T., Hada, T., Higashino, K., Urinary pseudouridine as a tumor marker in patients with small cell lung cancer. Clin. Chem. Acta 154 (1986), 125–132.
30. Nakano, K., Shindo, K., Yasaka, T., Reversed-phase high-performance liquid chromatographic investigation of mucosal nucleosides and bases and urinary modified nucleosides of gastrointestinal cancer patients. J. Chromatogr. 343 (1985), 21–33.
31. Kuchino, Y., Borek, E., Tumor-specific phenylalanine tRNA contains two supernumerary methylated bases. Nature (London), 271, 1976, 126.
32. Schbch, G., Heller-Schbch, G., Molekularbiologie und Klinische bedeutung des Stoffwechsels normaler und modifizierter Nucleobasen. Helv. Paediatr. Acta Suppl., 38, 1977, 1.
33. Speer, J., Gehrke, C.W., Kuo, K.C., Waalkes, T.P., Borek, E., TRNA breakdown products as markers for cancer. Cancer, 44, 1979, 2120.
34. McEntire, J.E., Kuo, K.C., Smith, M.E., Stalling, D.L., Richens, J.W. Jr., Zumwalt, R.W., Gehrke, C.W., Papermaster, B.W., Classification of Lung Cancer Patients and Controls by Chromatography of Modified Nucleosides in Serum. Cancer Research 49 (1989), 1057–1062.
35. G.B. Chheda, J.G. Antkowiak, H. Takita, A.K. Bhargava, H.A. Tworek, Evaluation of 5-carbamoylmethyluridine as an indicator of tumor burden in lung cancer patients, International Symposium on the Analysis of Nucleoside, Nucleotide and Oligonucleotide Compounds, Antwerp, Belgium, Sept. 1989.
36. U.R. Tjaden, High performance liquid chromatography of nucleosides, nucleotides and oligonucleotides, International Symposium on the Analysis of Nucleoside, Nucleotide and Oligonucleotide Compounds, Antwerp, Belgium, Sept. 1989.
37. Gehrke, C.W., Kuo, K.C., Ribonucleoside analysis by reversed-phase high performance liquid chromatography. J. Chromatogr. 471 (1989), 3–36.
38. Gehrke, C.W., Kuo, K.C., Davis, G.E., Suits, R.D., Waalkes, T.P., Borek, E., Quantitative high-perfomance liquid chromatography of nucleosides in biological materials. J. Chromatogr. 150 (1978), 455–476.
39. Davis, G.E., Suits, R.S., Kuo, K.C., Gehrke, C.W., Waalkes, T.P., Borek, E., High performance liquid chromatographic separation and quantitation of nucleosides in urine and some other biologic fluids. Clin. Chem. 23 (1977), 1427–1435.
40. Degrés, J., Keith, G., Kuo, K.C., Gehrke, C.W., Presence of phosphorylated o-ribosyl-adenosine in T-p-stem of yeast methionine initiator tRNA. Nucl. Acids Res. 17 (1989), 865–882.
41. Grossenbacher, A.M., Stadelmann, B., Heyer, W.D., Thuriaux, P., Kohli, J., Smith, C., Agris, P.F., Kuo, K.C., Gehrke, C.W., Antisuppressor mutations and sulfur carrying nucleoside in transfer RNAs of Schizosaccharomyces pombe. J. Biol. Chem. 261 (1986), 16351–16355.
42. F. Lustig, T. Boren, Y.S. Guindy P. Elias, T. Samuelson, C.W. Gehrke, K.C. Kuo, U. Lagerkvist, Codon discrimination and anticodon structural context, submitted to PNAS, Feb., 1989.
43. R.P. Martin, A.P. Sibler, C.W. Gehrke, K.C. Kuo, J.A. McCloskey, G. Dirheimer 5-Carboxymethylaminomethyluridine is found in the anticodon of yeast mitochondrial tRNAs recognizing two-codon families ending in a purine, Accepted, Biochemistry, Nov., 1989.
44. Waalkes, T.P., Abeloff, M.D., Ettinger, D.S., Woo, K.B., Gehrke, C.W., Kuo, K.C., Borek, E., Biological markers and small cell carcinoma of the lung: A clinical evaluation of urinary ribonucleosides. Cancer 50 (1982), 2457–2464.